Genus PLC
17 January 2008

For immediate release 17 January 2008

Genus plc
('Genus' or 'the Company')

Board Changes

Genus, a world leading animal genetics company, announces that Nigel Turner will be joining the Board as senior independent non-executive director with effect from today.

Nigel (aged 58), was Chairman of Numis Securities Ltd and Deputy Chairman of Numis Corporation plc from December 2005 to November 2007.

Previously he was Vice Chairman of ABN AMRO's Wholesale and Investment Bank in which he had specific responsibility for the Global Corporate Finance and Equity businesses. He joined the Dutch bank in 2000 from Lazard, where he was a partner for 15 years and sat on its Supervisory Board.

Nigel will chair the Company's Remuneration Committee and be a member of the Company's Audit and Nomination Committees.

Genus today also announces the retirement from the Board, with effect from today, of Edwin White. At the Company's Annual General Meeting held in November 2007, the Chairman announced that Edwin had indicated his intention to leave the Board, having been a Board member since the Company became publicly quoted seven years ago.

John Hawkins, Chairman of Genus, commented:

'We are delighted to welcome Nigel to the Board. With Genus' recent move to the Official List, Nigel's considerable experience will greatly benefit Genus in its next stage of development as a listed company.'

'I would also like to take this opportunity, on behalf of the Board, to thank Edwin for his valuable knowledge and contribution to the growth and success of Genus, and to wish him well in his retirement.'

There are no further details required to be disclosed under 9.6.13R of the Listing Rules of the UK Listing Authority.

For further information please contact:

Genus plc Tel: 01256 345970
John Hawkins, Chairman
Richard Wood, Chief Executive

Buchanan Communications Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks

About Genus

Genus sells added value products for livestock farming and food producers by creating advances to animal breeding through biotechnology. Its non-Genetically Modified Organism (GMO) technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Genus' worldwide sales are made in seventy countries under the trade marks 'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers use

Genus genetics in their herds to produce offspring with greater production efficiency, milk and meat output and quality. These offspring are used to supply the global dairy and meat supply chain.

Genus' competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and the Group's global production and distribution network.

Headquartered in Basingstoke, England, Genus companies operate in 30 countries on six continents, with research laboratories located in Madison, USA.

This information is provided by RNS
The company news service from the London Stock Exchange
OBKDADD